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Endometrial carcinoma is the most common inva-sive malignancy of the female genital tract. The typical presentation of endometrial cancer is 
postmenopausal bleeding and 75% to 80% of women are 
diagnosed with stage I disease. These patients have a good 
prognosis and are highly curable with hysterectomy with 
bilateral salpingo-oophorectomy with or without pelvic 
node dissection. The use of adjuvant treatment depends 
on the patients estimated risk of recurrence, mainly tu-
mor grade and depth of myometrial invasion.1,2 
In contrast to the early stage of disease, advanced 
endometrial cancer has poor prognosis. Traditionally, 
treatment for women with stage III endometrial cancer 
relies on radio-chemotherapy,3,4 while women with stage 
IV disease are treated with palliative chemotherapy.5 
Peritoneal metastases from endometrial carcinoma is 
considered metastatic disease and is treated with chemo-
therapy, the efficacy of which is low and, even in the case 
of responsive disease, rapid relapse and death is the rule.
We report a patient with stage IV endometrial car-
cinoma whose peritoneal and pelvic metastasis showed 
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a patient with recurrent endometrial cancer with multiple abdominal and pelvic tumoral masses was 
treated with re-irradiation combined with liposomal doxorubicin and oxaliplatin. a multiple field con-
formal technique was used to deliver a highly accelerated and hypofractionated scheme (15 fractions of 
3.5 Gy, within 19 days). Complete response was confirmed four months after therapy. four years later a 
lung metastasis appeared and was again treated with a similar course of therapy, once again resulting in 
a complete response. it is suggested that in the era of modern image-guided radiotherapy patients with 
endometrial cancer who have relapsed within or outside the loco-regional area, should be carefully 
assessed for an eventual gross tumor eradication using high-dose localized radiotherapy, leaving as the 
only target of chemotherapy the microscopic undetectable disease. 
long-standing complete remission after stereotactic re-
irradiation combined with chemotherapy. 
CASE
The patient was a 58-year old woman with a stage I en-
dometrioid adenocarcinoma grade III who underwent 
total hysterectomy and salpingo-oophorectomy fol-
lowed by postoperative radiotherapy. She received total 
tumor dose 50 Gy with a linear accelerator (ELECTA, 
Stockholm, Sweden) 18 MV using a four-field tech-
nique. The patient refused further intracavitary brachy-
therapy, due to substantial early radiation toxicity. 
Three years later she was referred to our department 
with the diagnosis of peritoneal metastasis and pelvic 
node relapse. She suffered from sever abdominal pain 
and cramps and local abdominal sensitivity. At least 
five discrete tumor masses 2-5 cm were evident in ab-
dominal/pelvic CT-scan. The patient was treated with 
conformal radiotherapy with multiple fields, combined 
with chemotherapy. The radiotherapy dose to the tumor 
masses was 52.5 Gy using an accelerated and hypofrac-
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tionated technique, delivering 15×3.5 Gy daily fractions 
within 19 days. This corresponds to a biological tumor 
dose around 70 Gy. Intravenous chemotherapy consist-
ed of 7 bi-weekly cycles of oxaliplatin (60mg/m2) and 
liposomal-doxorubicin (20 mg/m2) started on day 1 of 
radiotherapy. This combination therapy was well toler-
ated with diarrhea grade 1 and abdominal discomfort 
grade 1. No other side effects from chemotherapy or 
radiotherapy were noted. Four months after therapy, a 
complete response of the tumoral masses was confirmed 
in CT scans, leaving remnant scar tissue in the places of 
former tumors. The patient was alive with no evidence 
of disease and no severe late radiotherapy sequel (grade 
1 abdominal discomfort) for 4 years (Figure 1), when 
Figure 1. CT-images of abdominal (a1) and pelvic (a2, a) tumoral masses from recurrent endometrial carcinoma showing the fields 
and isodose curves of the radiotherapy performed . Complete response of the tumor masses is evident (arrows) at CT-scan performed 
4-years after therapy (b1, b2, b).
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a CT-scan showed a lung metastasis in the right upper 
lobe that was confirmed with PET-scan. The patients 
received conformal radiotherapy of the nodule using the 
same fractionation and chemotherapy as used for pelvic 
disease. Complete response of the mass was obtained 
and the patient is now free of disease (10 months after 
thoracic radiotherapy).
DISCUSSION
Although most patients with early stage endome-
trial cancer are cured with surgery with or without 
post-operative radiotherapy, 10% to 15% of them 
will relapse within the first 3 years after treatment.1,2 
Radical radio-chemotherapy or re-irradiation (in case 
of previous radiotherapy) is the treatment of choice 
for loco-regional recurrence.6 Distant metastasis are 
treated with polychemotherapy (doxorubicin, tax-
anes, cisplatin) and palliative radiotherapy when nec-
essary, but with poor results as the 5-year survival is 
less than 5%.5 Doxorubicin with cisplatin has long 
been considered the standard regimen of treating 
advanced or recurrent endometrial cancer, providing 
overall response rates of 40%.7 The combination of 
doxorubicin, cisplatin and paclitaxel showed a sta-
tistically significant improvement in response rate, 
progression-free and overall survival but toxicity is 
higher with the three drug regimen (thrombocytope-
nia, neurotoxicity).7 
This case report stresses the importance of careful 
evaluation of patients with peritoneal or, eventually lim-
ited metastatic disease to other organs, for the feasibil-
ity of the delivery of a high dose of radiotherapy local-
ized to the tumoral masses detectable on CT or MRI 
scans. Indeed, conformal radiotherapy planning and, 
even better IMRT intensity-modulated radiotherapy 
techniques, provide the tool for a safe radical treatment 
of gross disease, leaving it microscopically undetectable. 
The combination of liposomal doxorubicin with oxali-
platin was well tolerated during and after radiotherapy. 
The presented case is remarkable for the complete re-
sponse obtained with such techniques and the long dis-
ease-free survival achieved with radio-chemotherapy. 
Applying the same technique when lung metastasis ap-
peared 4-years after the first treatment, the disease was 
once again controlled.
We conclude that in the era of modern image-guid-
ed radiotherapy patients with endometrial cancer who 
have relapsed within or outside the loco-regional area, 
should be carefully assessed for an eventual gross tumor 
eradication using high dose localized radiotherapy, leav-
ing as the only target of chemotherapy the microscopic 
undetectable disease. 
